Newspaper logo  
 
 
Local News & Opinion

Ref. : Civic Events

Ref. : Arts & Education Events

Ref. : Public Service Notices

Travel
Books, Films, Arts & Education

11.25 Is Harvard Unfair to Asian-Americans?

11.25 Naomi Klein Lays Bare the Conflict Between Capitalism and the Climate

11.19 How DNA Is Reshaping How We See Ourselves—and Our History

11.18 Lobbying Used to Be a Crime: A Review of Zephyr Teachout’s New Book on the Secret History of Corruption in America

Letters
Open Letters:

Ref. : Letters to the editor

Health Care & Environment

11.25 Acid Rain Has Turned Canadian Lakes into a Kind of Jelly

11.25 Obama’s climate change envoy: fossil fuels will have to stay in the ground

11.24 Vancouver Experiments With Prescription Heroin

11.24 The Downside of the Boom

11.24 World bank to focus future investment on clean energy

11.23 The Piecemeal Assault on Health Care

11.23 NRG Seeks to Cut 90% of Its Carbon Emissions

11.23 Stampeding Black Elephants

News Media

11.24 Are Americans “Stupid” or Uninformed?

Daily FAIR Blog
The Daily Howler

Justice Matters

11.25 University of Virginia’s Image Suffers After Campus Rape Report

11.25 A Rape on Campus: A Brutal Assault and Struggle for Justice at UVA

11.22 Suffer Little Children

11.21 Icelandic bankers jailed for reckless loans made before crash

US Politics, Policy & Culture

11.25 Self-Segregation: Why It's So Hard for Whites to Understand Ferguson

11.25 The Gospel of Rudy Giuliani

11.25 Wave of violent civil unrest grips Ferguson after grand jury decision [videos]

11.24 The politics of infrastructure [video w/ads and transcript]

11.23 Grenade launchers, armored personnel carriers, and a military-grade helicopter among the lethal arsenal of police force who helped patrol Ferguson [photos]

11.22 Immigration Enriches You and Me

11.22 The United States of Thanksgiving [Interactive: click '+' sign for full recipes]

11.21 Ferguson Protests Are Coming to Your City

11.21 The U.S. government thinks China could take down the power grid

11.21 Obama on immigration: 'We are and always will be a nation of immigrants'

High Crimes?

11.22 Senate Democrats Clash With White House on C.I.A. Torture Report

Economics, Crony Capitalism

11.23 Top incomes soared as tax rates fell

11.23 Full Show: How Public Power Can Defeat Plutocrats [25:25 video and transcript]

11.22 Bill Black: Why the New York Fed Isn’t Trustworthy

11.22 Elizabeth Warren Blasts New York Fed President William Dudley [12:53 video]

11.22 Attorneys General for Sale

11.20 WSJ Reports: Bank of North Dakota Outperforms Wall Street

11.20 Elizabeth Warren Blasts FHFA’s Mel Watt: “You Haven’t Helped a Single Family” [5:23 video]

International
US air strikes in Syria driving anti-Assad groups to support Isis

11.24 'Mumbai is on the verge of imploding'

11.24 Israeli cabinet approves legislation defining nation-state of Jewish people

11.21 We need a new law to protect our wildlife from critical decline

We are a non-profit Internet-only newspaper publication founded in 1973. Your donation is essential to our survival.

You can also mail a check to:
Baltimore News Network, Inc.
P.O. Box 42581
Baltimore, MD 21284-2581
Google
This site Web
  Big Pharma Wins Big in Health Care Reform

COMMENTARY:

Big Pharma Wins Big in Health Care Reform

by James Ridgeway
First published in his blog Unsilent Generation yesterday, 22 March 2010
To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

The Republicans look a sour lot this morning, but the pharmaceutical industry, which helps foot the campaign bills of a sizeable chunk of members of both parties, is delighted with the legislation, and with its Democratic friends in the White House and on the Hill.

Members of Congress in both parties generally have lined up behind the insurance and pharmaceutical industries from the get go. So it should come as no surprise that the Democrats, who long ago gave up any pretence of opposing corporate power, found a way to accomodate the pharmaceutical companies on the way to its tepid reform. To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

In fact, the Dems actually made the drugsters look good, celebrating the industry’s generous “concessions” and “discounts” while ensuring that no real threat to Big Pharma’s profits would make their way into the final bill.

The industry’s main goal from the very beginning has been to fend off any government power to negotiate or seriously regulate drug prices–and this they did.

Big Pharma’s second big win was to prevent any measure that would have opened the way for American consumers to buy less expensive drugs abroad, especially from Canada.

At the same time, the supposed give-backs by the drug industry are projected to more than pay for themselves. The much-lauded discounts on brand name drugs for seniors in the Medicare prescription drug program, for example, are good for Big Pharma because they discourage oldsters from switching to generics.

And more insured people simply mean more money coming into the coffers, for Big Pharma as well as for the insurance industry.

Confirmation of the industry analysis came early in the day from the stock market, where drug stocks initially remained level; there certainly was no rush to dump shares, which is what would be expected if the bill actually represented any threat to profits. And by 1 p, EST, CNN Money was reporting a rally in health care stocks.

“I was unable to find anything in there that would cause me to have anxiety if I were a shareholder in a pharmaceutical company,” Ira Loss, a senior health-care analyst at the research firm Washington Analysis, told Dow Jones. According to the ticker story:

Billy Tauzin, who led the industry’s negotiations on health care with lawmakers, said overall drug makers fare well. “While we’re not totally happy,” Tauzin began, “we generally feel like it tracks with our principles.”

Sanofi-Aventis SA (SNY) Chief Executive Christopher Viehbacher said in an interview that the impact of the legislation will be neutral to slightly negative “but better for the industry than if healthcare reform didn’t pass.”

Tauzin, head of the Pharmaceutical Research and Manufacturers of America or PhRMA, and Viehbacher said getting protection for brand-name biologics is among the important provisions for the industry. Drug makers pushed hard to get 12 years of exclusive market protection while the White House and some lawmakers wanted to lower the protection to seven years.

Despite fees and rebates imposed by the legislation, “analysts say drug makers will end up recouping those costs through new customers: The bill would provide insurance coverage to an additional 32 million Americans.” The Dow Jones story continues:

Chalk up another good round for Pharma and Biotech in health care reform,” began a note to clients Friday from Concept Capital, a research firm.Ken Tsuboi, co-manager of the Allianz RCM Wellness Fund, sees the impact of bill, and its $90 billion in concessions over 10 years, as relatively minor in an industry that has annual global sales of about $750 billion, with about $300 billion in the U.S., and margins close to 30%.”I think that it is actually a pretty good deal for Pharma,” Tsuboi said.

The GOP, which purports to be the party of big business, ought to be applauding at least these portions of the health care reform—and perhaps when the cameras go away, some of them will quit bitching and count their blessings. As for the obnoxious Tea Party gang, if they start threatening the real power in this country, which is vested in corporations, they may well find themselves whipped and isolated.


Born in 1936, James Ridgeway has been reporting on politics for more than 45 years. He is currently Senior Washington Correspondent for Mother Jones, and recently wrote a blog on the 2008 presidential election for the Guardian online. He previously served as Washington Correspondent for the Village Voice; wrote for Ramparts and The New Republic; and founded and edited two independent newsletters, Hard Times and The Elements.

Ridgeway is the author of 16 books, including The Five Unanswered Questions About 9/11, It’s All for Sale: The Control of Global Resources, and Blood in the Face: The Ku Klux Klan, Aryan Nations, Nazi Skinheads, and the Rise of a New White Culture. He co-directed a companion film to Blood in the Face and a second documentary film, Feed, and has co-produced web videos for GuardianFilms.

Additional information and samples of James Ridgeway’s work can be found at JamesRidgeway.net and at his newest web site, Solitary Watch.

This article is republished in the Baltimore Chronicle with permission of the author.



Copyright © 2010 The Baltimore News Network. All rights reserved.

Republication or redistribution of Baltimore Chronicle content is expressly prohibited without their prior written consent.

Baltimore News Network, Inc., sponsor of this web site, is a nonprofit organization and does not make political endorsements. The opinions expressed in stories posted on this web site are the authors' own.

This story was published on March 23, 2010.
 



Public Service Ads:
Verifiable Voting in Maryland